Militia Capital Management LLC Makes New $1.89 Million Investment in Abivax SA Sponsored ADR $ABVX

Militia Capital Management LLC acquired a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 1st quarter, HoldingsChannel reports. The fund acquired 17,000 shares of the company’s stock, valued at approximately $1,893,000.

Other hedge funds also recently modified their holdings of the company. TCG Crossover Management LLC lifted its position in shares of Abivax by 17.4% during the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after acquiring an additional 1,055,000 shares during the period. UBS Group AG grew its holdings in Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares during the period. Darwin Global Management Ltd. increased its stake in Abivax by 0.4% in the fourth quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock valued at $439,714,000 after purchasing an additional 14,000 shares in the last quarter. Morgan Stanley increased its stake in Abivax by 114.3% in the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in shares of Abivax by 90.0% during the fourth quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock valued at $256,224,000 after purchasing an additional 900,000 shares during the period. Institutional investors own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ABVX shares. Wolfe Research set a $136.00 price objective on shares of Abivax in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Friday, July 17th. Jefferies Financial Group upgraded Abivax from a “hold” rating to a “buy” rating and increased their price target for the stock from $108.00 to $158.00 in a report on Tuesday, June 30th. BTIG Research boosted their price objective on Abivax from $150.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $152.50.

Abivax Price Performance

ABVX opened at $129.73 on Thursday. Abivax SA Sponsored ADR has a fifty-two week low of $62.50 and a fifty-two week high of $148.83. The firm has a market capitalization of $11.31 billion, a PE ratio of -24.90 and a beta of 0.87. The company’s 50-day moving average is $117.57 and its 200 day moving average is $118.22.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. As a group, analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.